Fund Generet Call 2020 for Belgium

 

The Fund wants to support research on rare diseases to better understand the processes (causes and mechanisms) underpinning rare diseases and/or to turn fundamental discoveries into better prevention, diagnosis or treatment of patients.

This annual award of 1.000.000 € aims to catalyse the research agenda on rare diseases in Belgium and beyond. The amount will be paid in 2 phases of 500.000 euros. The second support is conditional to a positive midterm review.

The Fund Generet wishes to support for the third time a top researcher in Belgium with outstanding scientific achievements who has already developed or is willing to develop a research line in rare diseases. The Fund encourages strongly international and interdisciplinary collaboration. Part of the budget may be outsourced for supporting international expenses.

This call is launched in partnership with the FNRS and the FWO.

The Fund wants to support research on rare diseases to better understand the processes (causes and mechanisms) underpinning rare diseases and/or to turn fundamental discoveries into better prevention, diagnosis or treatment of patients.

This annual award of 1.000.000 € aims to catalyse the research agenda on rare diseases in Belgium and beyond. The amount will be paid in 2 phases of 500.000 euros. The second support is conditional to a positive midterm review.

The Fund Generet wishes to support for the third time a top researcher in Belgium with outstanding scientific achievements who has already developed or is willing to develop a research line in rare diseases. The Fund encourages strongly international and interdisciplinary collaboration. Part of the budget may be outsourced for supporting international expenses.

This call is launched in partnership with the FNRS and the FWO.

A high level internationally established researcher in Belgium with outstanding scientific achievements who has already developed or is willing to develop a research line in rare diseases is encouraged to apply.

Deadline is 20 April 2020.